Three Veni grants for CARIM scientists
The Netherlands Organisation for Scientific Research (NWO) has awarded a Veni grant to three CARIM scientists. In total 154 young scientists receive a Veni grant worth up to 250,000 euros. The grant provides laureates with the opportunity to further elaborate their own ideas druing a period of three years.
Thomas van Sloten (Dept. of Internal Medicine) - Small vessels, big impact: does microvascular dysfunction lead to late-life depression?
Late-life depression is common, but its underlying mechanisms are largely unknown. Thomas will investigate whether dysfunction of the smallest vessels in the brain leads to depression by causing subtle brain changes. He will use a unique combination of genetic, advanced brain imaging and pharmacoepidemiologic data from large studies, including The Maastricht Study.
Matthijs Cluitmans (Dept. of Cardiology) - Personalized medicine in sudden cardiac death: Integrating advanced imaging with computer modelling
This personal career grant allows Matthijs to study arrhythmia mechanisms in sudden cardiac death. Such life-threatening heart-rhythm disorders can develop suddenly in apparently healthy individuals, without evident substrate. In his study, Matthijs will use new imaging techniques to detect the substrate in patients. He will then study the exposed substrate with computer simulations to understand the mechanisms of these rhythm disorders in an individual patient. In the future, such personalized computer simulations might help to predict an individual’s risk for sudden cardiac death and choose appropiate treatment.
Emiel van der Vorst (Dept. of Pathology) - Targeting immune-lipid crosstalk in cardio-metabolic diseases: focus on High-Density Lipoproteins dependent regulation of chemokine-receptor signaling
Until now, therapies for cardiovascular diseases have primarily focused on specific atherogenic drivers, e.g. dyslipidemia or inflammation. However, recently it became evident that there is considerable crosstalk between these features. In this project, he will explore two entirely new ways of this so called immune-lipid crosstalk, where chemokine/chemokine-receptor activity is modulated by High-Density Lipoproteins, defining unprecedented targets for intervention in this crosstalk that underlie many cardio-metabolic disorders.